Dalian Wanchunbulin Pharmaceutical

Dalian Wanchunbulin Pharmaceuticals is a clinical-stage biopharmaceutical company based in China and a majority-owned subsidiary of BeyondSpring. The company is dedicated to the development and commercialization of innovative cancer therapies, with a primary focus on its lead asset, plinabulin. Plinabulin is a first-in-class selective immunomodulating microtubule-binding agent (SIMBA) designed to prevent chemotherapy-induced neutropenia (CIN) and treat various cancers, including non-small cell lung cancer (NSCLC). In August 2026, the company's New Drug Application (NDA) for plinabulin injection concentrate was accepted for review by China's National Medical Products Administration (NMPA). Wanchunbulin holds the exclusive rights to plinabulin in the Greater China region and continues to advance its clinical development despite ongoing commercial disputes with its regional partner, Jiangsu Hengrui Pharmaceuticals.